Ofatumumab
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Ofatumumab |
| DrugBank ID | DB06650 |
| Brand Names (EU) | Kesimpta |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 99.88% |
Approved Indication (EMA)
Kesimpta is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features (see section 5.1).
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | acute lymphoblastic/lymphocytic leukemia | 99.88% | DL |
| 2 | pregerminal center chronic lymphocytic leukemia/small lymphocytic lymphoma | 99.77% | DL |
| 3 | chronic lymphocytic leukemia/small lymphocytic lymphoma with immunoglobulin heavy chain variable-region gene somatic hypermutation | 99.77% | DL |
| 4 | Richter syndrome | 99.74% | DL |
| 5 | follicular lymphoma | 99.70% | DL |
| 6 | leukemia, lymphocytic, susceptibility to | 99.59% | DL |
| 7 | chronic lymphocytic leukemia/small lymphocytic lymphoma | 99.55% | DL |
| 8 | metastatic neoplasm | 99.50% | DL |
| 9 | malignant spiradenoma | 99.48% | DL |
| 10 | Langerhans cell histiocytosis | 99.34% | DL |
| 11 | histiocytic and dendritic cell neoplasm | 98.99% | DL |
| 12 | childhood mediastinal neurogenic neoplasm | 98.94% | DL |
| 13 | childhood germ cell tumor | 98.94% | DL |
| 14 | childhood carcinoid tumor | 98.94% | DL |
| 15 | Hodgkins lymphoma | 98.93% | DL |
| 16 | optic nerve glioma | 98.93% | DL |
| 17 | childhood ependymoma | 98.93% | DL |
| 18 | childhood choroid plexus neoplasm | 98.92% | DL |
| 19 | mantle cell lymphoma | 98.91% | DL |
| 20 | neoplasm of mature B-cells | 98.89% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.